Clinical Update on Inflammatory Disorders of the Gastrointestinal Tract

1 - Cover [Seite 1]
2 - Contents [Seite 6]
3 - Preface [Seite 8]
4 - Non-Alcoholic Fatty Liver Disease [Seite 10]
4.1 - Abstract [Seite 10]
4.2 - Nomenclature [Seite 10]
4.3 - Epidemiology and Natural History [Seite 11]
4.4 - Pathogenesis [Seite 13]
4.5 - Clinical Features and Investigation [Seite 15]
4.6 - Therapy [Seite 16]
4.7 - Conclusions [Seite 21]
4.8 - References [Seite 21]
5 - Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options [Seite 24]
5.1 - Abstract [Seite 24]
5.2 - Cellular and Molecular Mechanisms of Fibrosis in the GI Tract [Seite 24]
5.3 - Liver Fibrosis [Seite 32]
5.4 - Pancreatic Fibrosis [Seite 33]
5.5 - Intestinal Fibrosis [Seite 34]
5.6 - Clinical Evaluation of Fibrosis Progression/Regression [Seite 34]
5.7 - Potential Anti-Fibrogenic Strategies [Seite 35]
5.8 - References [Seite 36]
6 - Chronic Hepatitis B: Pathophysiology, Diagnosis and Treatment Options [Seite 41]
6.1 - Abstract [Seite 41]
6.2 - Phases of Hepatitis B Infection [Seite 43]
6.3 - Role of Viral Load [Seite 43]
6.4 - Immunopathogenesis [Seite 44]
6.5 - Treatment Options in Chronic Hepatitis B [Seite 46]
6.6 - Summary [Seite 48]
6.7 - References [Seite 49]
7 - Chronic Hepatitis C: Pathophysiology, Diagnosis and Treatment Options [Seite 51]
7.1 - Abstract [Seite 51]
7.2 - Viral Cycle [Seite 51]
7.3 - Interferon Signalling and HCV Infection [Seite 54]
7.4 - Innate and Adaptive Immunity to HCV Infection [Seite 56]
7.5 - Progression of Fibrosis in Hepatitis C [Seite 58]
7.6 - Predictive Factors of Response to Treatment [Seite 59]
7.7 - Genome-Wide Association Studies Identified SNPs in the IL28B Region Associated with Response to Treatment [Seite 60]
7.8 - Molecular Signatures of Response in Liver [Seite 60]
7.9 - Standard of Care: Combined PEG-IFN Plus Ribavirin [Seite 62]
7.10 - Specifically Targeted Antiviral Therapy for HCV [Seite 62]
7.11 - Conclusion [Seite 64]
7.12 - Acknowledgment [Seite 64]
7.13 - References [Seite 65]
8 - Clinical Update on Inflammatory Disorders of the GI Tract: Liver Transplantation [Seite 68]
8.1 - Abstract [Seite 68]
8.2 - Primary Sclerosing Cholangitis [Seite 69]
8.3 - Autoimmune Hepatitis [Seite 74]
8.4 - PSC and AIH: Similarities and Differences [Seite 76]
8.5 - References [Seite 78]
9 - Hepatocellular Carcinoma [Seite 81]
9.1 - Abstract [Seite 81]
9.2 - Incidence and Epidemiology [Seite 81]
9.3 - Screening and Surveillance [Seite 82]
9.4 - Diagnosis and Staging [Seite 82]
9.5 - Treatment [Seite 83]
9.6 - Surgical Interventions for Advanced HCC [Seite 84]
9.7 - Locoablative Therapies with Curative Intent [Seite 86]
9.8 - Established palliative Therapeutic Intervention for Advanced HCC [Seite 87]
9.9 - Transarterial Chemoembolization [Seite 87]
9.10 - Drug Treatment for Advanced HCC [Seite 88]
9.11 - Non-Established and Experimental Treatment Options [Seite 89]
9.12 - References [Seite 89]
10 - Coeliac Disease [Seite 92]
10.1 - Abstract [Seite 92]
10.2 - Coeliac Disease, Epidemiology and Symptoms [Seite 92]
10.3 - Pathogenesis of Coeliac Disease [Seite 94]
10.4 - Genetic and Other Risk Factors [Seite 98]
10.5 - Oral Tolerance to Gluten [Seite 98]
10.6 - Intestinal Gluten Transport [Seite 98]
10.7 - Novel Therapies for Coeliac Disease [Seite 99]
10.8 - Conclusions [Seite 99]
10.9 - Acknowledgments [Seite 101]
10.10 - References [Seite 101]
11 - Anti-TNF Therapy in Inflammatory BowelDiseases [Seite 104]
11.1 - Abstract [Seite 104]
11.2 - Methods [Seite 105]
11.3 - Results [Seite 105]
11.4 - Conclusion [Seite 113]
11.5 - References [Seite 114]
12 - Role of Epithelial Cells in Inflammatory Bowel Disease [Seite 117]
12.1 - Abstract [Seite 117]
12.2 - Endoplasmic Reticulum Stress [Seite 118]
12.3 - Autophagy [Seite 120]
12.4 - NOD2 [Seite 121]
12.5 - Organic Cation Transporters [Seite 122]
12.6 - NF?B [Seite 123]
12.7 - Conclusion [Seite 124]
12.8 - References [Seite 124]
13 - GI Immune Response in Functional GI Disorders [Seite 127]
13.1 - Abstract [Seite 127]
13.2 - Introduction [Seite 127]
13.3 - Presence of Inflammation [Seite 128]
13.4 - Summary [Seite 132]
13.5 - References [Seite 132]
14 - Probiotics in GI Diseases [Seite 135]
14.1 - Abstract [Seite 135]
14.2 - Probiotics [Seite 135]
14.3 - Inflammatory Bowel Disease [Seite 136]
14.4 - H. pylori Infection [Seite 139]
14.5 - Irritable Bowel Syndrome [Seite 140]
14.6 - Diverticular Disease [Seite 141]
14.7 - Conclusions [Seite 141]
14.8 - References [Seite 142]
15 - Microscopic Colitis [Seite 144]
15.1 - Abstract [Seite 144]
15.2 - Background [Seite 144]
15.3 - Epidemiology [Seite 144]
15.4 - Clinical Features [Seite 145]
15.5 - Pathophysiology [Seite 146]
15.6 - Treatment [Seite 147]
15.7 - Budesonide [Seite 147]
15.8 - Prednisolone [Seite 149]
15.9 - Bismuth Subsalicylate [Seite 149]
15.10 - Mesalazine with or without Cholestyramine [Seite 149]
15.11 - Probiotics [Seite 149]
15.12 - Boswellia serrata Extract [Seite 150]
15.13 - Antidiarrhoeals [Seite 150]
15.14 - Immunosuppressive Therapy [Seite 150]
15.15 - Surgical Therapy [Seite 150]
15.16 - Conclusion [Seite 151]
15.17 - References [Seite 152]
16 - Inflammatory Proteins as Prognostic Markersin Acute Pancreatitis [Seite 155]
16.1 - Abstract [Seite 155]
16.2 - Insights into Pathophysiology [Seite 156]
16.3 - Prediction of Severity [Seite 157]
16.4 - Inflammatory Proteins as Prognostic Markers [Seite 157]
16.5 - Conclusions [Seite 162]
16.6 - References [Seite 162]
17 - Antibiotics, Probiotics and Enteral Nutrition: Means to Prevent Infected Necrosis in AP [Seite 166]
17.1 - Abstract [Seite 166]
17.2 - Introduction [Seite 166]
17.3 - Antibiotics [Seite 167]
17.4 - Probiotics [Seite 168]
17.5 - Enteral Nutrition [Seite 170]
17.6 - Summary [Seite 172]
17.7 - References [Seite 172]
18 - IKK/NF-?B/Rel in Acute Pancreatitis and Pancreatic Cancer: Torments of Tantalus [Seite 175]
18.1 - Abstract [Seite 175]
18.2 - Transcription Factor NF-?B [Seite 176]
18.3 - IKK/NF-?B/Rel Pathway in Acute Pancreatitis [Seite 178]
18.4 - IKK/NF-?B/Rel Pathway in Pancreatic Cancer [Seite 180]
18.5 - Conclusion [Seite 182]
18.6 - References [Seite 183]
19 - Immunotherapy of Pancreatic Carcinoma: Recent Advances [Seite 185]
19.1 - Abstract [Seite 185]
19.2 - Immunotherapeutical Approaches [Seite 186]
19.3 - Summary [Seite 192]
19.4 - References [Seite 192]
20 - Helicobacter pylori Infection: To Eradicate or Not to Eradicate [Seite 195]
20.1 - Abstract [Seite 195]
20.2 - Peptic Ulcer Disease [Seite 196]
20.3 - Gastro-oesophageal Reflux Disease [Seite 198]
20.4 - Functional Dyspepsia [Seite 198]
20.5 - H. pylori Therapy for the Prevention of Gastric Cancer [Seite 200]
20.6 - MALT Lymphoma [Seite 203]
20.7 - Extragastric Diseases [Seite 204]
20.8 - Conclusions [Seite 204]
20.9 - References [Seite 205]
21 - Carcinogenesis and Treatment of Gastric Cancer [Seite 208]
21.1 - Abstract [Seite 208]
21.2 - H. pylori and Gastric Carcinogenesis [Seite 209]
21.3 - Inflammation, Atrophy, Metaplasia and Intestinal-Type Gastric Cancer [Seite 209]
21.4 - Mechanisms Linking Inflammation and Cancer [Seite 211]
21.5 - Molecular Alterations and Oncogenic Pathways in Gastric Cancer [Seite 212]
21.6 - Treatment of Gastric Cancer [Seite 213]
21.7 - Neoadjuvant Therapy [Seite 213]
21.8 - Adjuvant Therapy [Seite 214]
21.9 - Palliative Chemotherapy [Seite 216]
21.10 - References [Seite 217]
22 - Author Index [Seite 220]
23 - Subject Index [Seite 221]
24 - Back cover [Seite 226]